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The ephrin receptor A4 (EphA4) is one of the receptors in the
ephrin system that plays a pivotal role in a variety of cell-cell inter-
actions, mostly studied during development. In addition, EphA4
hasbeen found toplay a role in cancerbiologyaswell as in thepatho-
genesis of several neurological disorders suchas stroke, spinal cord
injury, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and
Alzheimer’s disease. Pharmacological blocking of EphA4 has been
suggested to be a therapeutic strategy for these disorders. There-
fore, the aim of our study was to generate potent and selective
Nanobodies against the ligand-binding domain of the human
EphA4 receptor.We identified twoNanobodies, Nb 39 andNb 53,
that bind EphA4 with affinities in the nanomolar range. These
Nanobodies were most selective for EphA4, with residual binding
to EphA7 only. UsingAlphascreen technology, we found that both
Nanobodies displaced all known EphA4-binding ephrins from the
receptor. Furthermore,Nb39 andNb53 inhibited ephrin-induced
phosphorylationof theEphA4protein inacell-basedassay.Finally,
in a cortical neuron primary culture, both Nanobodies were able
to inhibit endogenous EphA4-mediated growth-cone collapse
induced by ephrin-B3. Our results demonstrate the potential of
Nanobodies to target the ligand-binding domain of EphA4. These
Nanobodiesmaydeservefurtherevaluationaspotential therapeutics
in disorders in which EphA4-mediated signaling plays a role.
Ephrinreceptors, the largest familyof receptor-tyrosinekinases,
are subdivided in A- and B-class receptors. In mammals there are
nine EphA receptors (EphA1-EphA8, EphA10) that interact
with five ephrin-A ligands (ephrin-A1–ephrin-A5) and five EphB
receptors (EphB1–EphB4, EphB6) that interact with three eph-
rin-B ligands (ephrin-B1–ephrin-B3) (1). There is some interclass
promiscuity, as EphA4 can also interact with ephrin-B ligands,
whereas EphB2 also interacts with ephrin-A5 (2–4).
The ephrin system plays a major role in a variety of cell-cell
interactions. In the developing nervous system it is pivotal as an
axonal guidance system,whereas in the adult brain it is involved
in synaptic plasticity and long-term potentiation (5, 6). Impor-
tantly, the ephrin system also plays a role in cancer biology and
in the pathogenesis of several neurological disorders (5). EphA4
is up-regulated in spinal cord injury, traumatic brain injury, and
stroke, and blocking of the receptor increases functional recov-
ery in models for these conditions (7–9). Interestingly, antago-
nism of EphA4 improves long-term potentiation defects in a
mousemodel for Alzheimer’s disease and improves outcome in
animal models for amyotrophic lateral sclerosis (ALS)9 and
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stroke (9–12). EphA4 expression is inversely correlated with
survival time inALS patients, which suggests that EphA4 is also
involved in ALS human pathology (11). These findings suggest
that EphA4 inhibitionmay have the potential for the treatment
of neurological disorders.
Inhibition of EphA4 signaling can be accomplished by target-
ing the ATP-binding pocket in the kinase domain or by block-
ing the interaction with ephrin ligands (13, 14). Because the
ATP-binding pocket is highly conserved among tyrosine
kinases it is very difficult to develop selective inhibitors (13).
Alternatively targeting the ligand-binding domain (LBD) cer-
tainly allows the development of more selective compounds,
but this poses several other problems. On one hand, the protein
interaction surface to be covered is large; 900 Å2 in the case of
EphA4 (15, 16). On the other hand, the LBD is dynamic by
nature, as EphA4 can adopt a conformation similar to other
EphA receptors upon interaction with ephrin-A ligands or
characteristics of EphB receptors when interacting with eph-
rin-B ligands (2, 4, 17).
Nevertheless several peptides and small molecules have
been identified that bind the EphA4 LBD and block its inter-
action with ephrin ligands (18–22). One of these EphA4
antagonists is the KYL peptide, which has been extensively
characterized and shown to be effective in several in vitro
assays as well as in in vivo spinal cord injury and ALS models
(11, 19, 23, 24), suggesting the potential of an EphA4-based
therapeutic approach.
The aim of this study was to develop highly selective and
potent EphA4 inhibitors. To achieve this goal, we took advan-
tage of theNanobody technology (25–27).Nanobodies (Nbs) or
VHHs are small antigen-binding fragments derived from cam-
elid heavy-chain-only antibodies that are devoid of light chains.
They are superior to conventional antibodies in terms of stabil-
ity, solubility, and immunogenicity (27). Furthermore, they are
much smaller than conventional antibodies (12–15 kDa versus
150–160 kDa) and can penetrate small clefts and cavities (28).
We were able to generate Nbs against the LBD of the EphA4
receptor. Two of these Nbs specifically bind the EphA4 recep-
tor with nanomolar affinities and block ephrin-induced EphA4
phosphorylation and EphA4-mediated actin remodeling in a
growth-cone collapse assay. These results demonstrate the
potential of Nbs to selectively target the LBD of the EphA4
receptor. These Nbs may be useful as a therapeutic strategy in
disorders in which EphA4 plays a pathogenic role.
Results
Generation of anti-EphA4 LBDNbs
An alpaca was immunized with recombinant human EphA4
LBD according to standard procedures (29). In addition to con-
ventional antibodies, alpacas also produce heavy-chain-only
antibodies in response to an immunogen. A phagemid library
displaying Nbs was constructed from the RNA extracted from
peripheral blood lymphocytes and transformed in Escherichia
coli TG1 cells. A library of 2  108 independent transfor-
mants was obtained, and87% of transformants harbored the
vector with the right insert size. Phage particles were generated
and subjected to panning. After four consecutive rounds of
panning, we obtained 41 colonies that expressed antigen-
specific Nbs in their periplasmic extracts, as determined by
ELISA. Sequencing of the Nb genes from these 41 positive
colonies resulted in 15 different Nbs. Characteristically, Nbs
contain three complementary-determining regions that con-
tribute to antigen-binding specificity. Based on sequence ho-
mology, they belonged to nine different clonally unrelated
B-cell clones (Fig. 1). Nbs belonging to the same group
showed very high sequence similarity, suggesting that they
are originating from clonally related B-cells that underwent
hypermutation. Nbs 39, 16, 71, 28, and 22 most likely belong
to unrelated B-cell clones.
Expression of the anti-EphA4 LBDNbs
Phagemids encoding the Nbs of interest were transformed
intoWK6E. coli cells to allow expression of theNbswithout the
pIII fusion. The expressed Nbs were recovered from the
periplasmic extracts and purified. Their purity was analyzed by
Coomassie-stained SDS-polyacrylamide gels, and their identity
was determined with Western blot detection using His6 tag
(data not shown). All Nbs could be detected at a position cor-
responding to 15 kDa. However, there were obvious differ-
ences in expression levels of theNbs (data not shown). Concen-
Figure 1. Amino acid sequence of 15 different anti-EphA4 LBD Nbs. Nbs were numbered according to Kabat numbering with reference sequence
VH3–23/JH5 (human germ line sequence on average most closely related to Nanobody sequences) on top. The complementary determining regions were
assigned according to the AbM definitions (75) and are shown with a gray background. The Nbs belonged to nine clonally unrelated B-cell clones, and the
different groups are shown alternatively in black and red. According to the amino acid sequences Nb 90 and 60, Nb 19 and 57, Nb 34 and 47, and Nb 31, 50, 10,
and 53 belonged to the same group. Nb 39, 16, 71, 28, and 22 belonged to unrelated B-cell clones.
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tration of poorly expressedNbs 90, 16, 71, 28, and 10 resulted in
protein aggregation. Therefore, we did not include theseNbs in
further analyses.
Analysis of EphA4 binding
We next determined whether the Nbs recognized EphA4
under reducing, none-native conditions. None of them bound
recombinant EphA4 (data not shown) on Western blot. An
EphA4monoclonal antibody was used as a positive control and
readily bound the denatured recombinant protein. These data
suggested that the Nbs target a conformational epitope on the
EphA4 LBD. To test whether the Nbs were indeed able to bind
native EphA4, we performed immunoprecipitation experi-
ments (Fig. 2). Nbs 31, 39, 50, 53, and 57 precipitated EphA4
protein, and EphA4 in turn precipitated these Nbs (data shown
only for Nbs 53 and 39 in Fig. 2, A and B). In contrast to the
other Nbs, Nb 22 showed lower binding to mouse EphA4 com-
pared with human EphA4 (Fig. 2C). Nbs 19, 34, and 47 revealed
nonspecific binding to the beads and to recombinant ephrin-B2
(data shown only for Nb 19 and 47 in Fig. 2,D and E). Nb 60 did
not shownonspecific binding to the beads but precipitatedwith
recombinant ephrin-B2, indicating cross-reactivity with eph-
rin-B2 (Fig. 2F).
To identify the Nbs with the highest affinity, we determined
their binding kinetics to EphA4 using surface plasmon reso-
nance (SPR). The EphA4 LBD was immobilized onto the chip
and Nbs (1–300 nM) were used as the analyte. SPR analyses
revealed that Nbs 34 and 47 do not bind to the EphA4 LBD
(Table 1). Nbs 22, 31, 39, 50, 53, 57, and 60 bound in the low
nanomolar range, whereas Nb 19 only interacted with EphA4
LBD in the higher nanomolar range (Table 1).
We next investigated the affinity of the Nbs for full-length
recombinant human and mouse EphA4 receptor. Most Nbs
showed similar binding to the full-length receptor as to the
EphA4 LBD. Nb 22 showed a 2-fold difference in binding affin-
ity between human andmouse EphA4, in agreement with what
we found in immunoprecipitation experiments (Fig. 2C). Based
on these results, we selected seven Nbs (60, 57, 39, 22, 31, 50,
and 53) with affinities in the nanomolar range for both the
EphA4 LBD and the full-length receptor.
Figure 2. Nbs bind native EphA4 LBD. Nbs and EphA4 co-immunoprecipitated (IP) together, both when immunoprecipitating different Nbs (left panel) or
when immunoprecipitatingEphA4 (rightpanel).AandB, Nb53andNb39could capture EphA4andcouldbecapturedbyEphA4.C, Nb22 showed lower affinity
for mouse EphA4 compared with human EphA4. D and E, Nb 19 and 47 showed unspecific binding to the beads. F, Nb 60 showed cross-reactivity with
ephrin-B2, which was performed as a negative control experiment.
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Cross-reactivity with other Eph receptors
Because the homology between the different Eph receptors is
very high, we used Alphascreen technology to study the speci-
ficity of the Nbs generated. All Eph receptors tested showed
binding with ephrin-A5 and/or ephrin-B2, indicating that all
receptors adopted their correct conformation. Ephrin-A5
interacted with all EphA receptors and with EphB2, as has been
previously shown (data not shown) (3). Ephrin-B2 interacted
with all EphB receptors and EphA4 but not with EphB6, for
whichno ligands have been identified so far (data not shown) (4,
30). The control Nb did not bind to any of the Eph receptors as
expected (data not shown).
Alphascreen analyses showed thatNb 60 interactedwith sev-
eral Eph receptors other than EphA4 (Fig. 3A), in agreement
with the immunoprecipitation results obtained with this Nb
(Fig. 2F). Nb 57 bound EphA4 but also EphA3 and EphA7, and
Nb 50 bound EphA4 but also EphA3, EphA6, EphA7, and
EphA8 (Fig. 3, B and F). Nbs 22, 31, 39, and 53 were almost
completely selective for EphA4, although some binding to
EphA7 was detected (Fig. 3, C, D, E, and G). We, therefore,
selected the latter four for further screening.
Competition with ephrin ligands for the interaction with
EphA4
EphA4 interacts with most of the ephrins (2, 4). We, there-
fore, investigated whether the selected Nbs were able to dis-
place the ligands from the EphA4 receptor.We determined the
optimal concentration for the different ephrin ligands using a
fixed concentration of the EphA4 LBD to avoid the hooking
effect, and we added increasing concentrations of the Nbs. The
control Nb did not compete with any ephrin ligand for the
interactionwith EphA4, as expected (data not shown). TheKYL
peptide, a known EphA4 inhibitor, was used as a positive
control.
Nb 39 and Nb 53 completely displaced all ephrin ligands
from EphA4 binding in a concentration range lower than the
KYL peptide (Fig. 4, A–H). Nbs 22 and 31 were less potent. Nb
22 completely displaced ephrin-A3 (Fig. 4C) and almost com-
pletely displaced ephrin-B ligands (Fig. 4, F–H) from EphA4
binding, but no full displacement of the other ephrin-A ligands
was obtainedwith the concentrations tested (Fig. 4,A,B,D, and
E). Its potency was comparable to that of the KYL peptide. Nb
31 completely displaced ephrin-A1, ephrin-B1, and ephrin-B2
at lower concentrations than the KYL peptide (Fig. 4, A, F, and
G) and completely displaced ephrin-A3 with concentrations
similar to the KYL peptide (Fig. 4C). However, ephrin-A2, eph-
rin-A4, ephrin-A5, and ephrin-B3 could not be completely dis-
placed with the concentrations tested (Fig. 4, B, D, and E).
These data show that Nbs 39 and 53 were able to block the
interaction of all ephrin ligands with the EphA4 LBD.
To examine the potency of Nb 39 and 53 in inhibiting
another Eph receptor, EphA7, comparedwith EphA4,we deter-
mined the capacity of these two Nbs to modify the interaction
between EphA7 and ephrin-A5 in a competition assay. We
determined the optimal binding concentrations of EphA7 and
ephrin-A5. At a concentration in which Nb 39 and Nb 53 were
able to inhibit binding of ephrin-A5 to EphA4 (Fig. 4E), only
partial inhibition of the interaction between EphA7 and eph-
rin-A5 could be detected (Fig. 5). A control Nb did not compete
with ephrin-A5-binding to EphA7 (data not shown).
Inhibition of ephrin-induced EphA4 activation
To assess the antagonistic properties of the Nbs, we tested
their effect on ephrin-induced EphA4 phosphorylation (31).
Upon ephrin binding, Eph receptors are dimerized and acti-
vated by autophosphorylation (phosphorylation of tyrosine res-
idues in the kinase domain and juxtamembrane region) (31).
After clustering, the phosphorylated tyrosine residues form
binding sites for cytoplasmic targets with Src homology 2 (SH2)
or phosphotyrosine binding (PTB) domains (31, 32). In general,
EphA4 phosphorylation results in cell-cell segregation, in this
way regulating cytoskeleton dynamics and morphology (1).
Ephrin-induced phosphorylationwas examined using the Path-
Hunter assay in U2OS cells. Cells were stimulated with eph-
rin-A1 with or without the presence of an EphA4 antagonist,
and the resulting EphA4 phosphorylation was measured. The
control Nb did not have any effect on receptor phosphorylation
(data not shown). The KYL peptide achieved complete inhibi-
tion of ephrin-A1-induced phosphorylation with an IC50 value
of 53 M (Fig. 6). Nbs 39 and 53 also completely inhibited eph-
rin-A1-induced phosphorylation at lower concentrations than
the KYL peptide, with an IC50 of 170 nM and 261 nM, respec-
Table 1
Overview of the EphA4-Nanobody binding constants
Association constants (ka1 and ka2), dissociation constants (kd1 and kd2) and equilibration constants (KD) were determined by SPR through kinetics analysis. SPR analyses
were performed in duplicate. Alternating red and black colors indicate different Nb groups based on their clonal origin.
EphA4 inhibiting Nanobodies
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tively (Fig. 6). These data indicate that Nbs 39 and 53 are 200–
300 times more potent than the KYL peptide in inhibiting eph-
rin-A1-induced phosphorylation of the EphA4 receptor.
Inhibition of ephrin-induced growth-cone collapse
A common cellular response downstream of Eph receptor
activation is actin cytoskeleton reorganization, leading to cell
morphology changes (1, 33). Ephrin-B3 treatment of cortical
neurons in vitro induces collapse of growth cones at the tip
of the neurites by reorganization of actin filaments (34, 35). Corti-
cal neurons lacking functional EphA4 show insensitivity to
the ephrin-B3-mediated growth-cone collapse, suggesting
that this effect is EphA4-mediated (36). We next determined
whether the Nbs are also able to antagonize a cellular response
such as growth-cone collapse induced by an EphA4 receptor
agonist. To this end, we investigated their effect on the eph-
rin-B3 induced inhibition of neurite elongation in E17.5 embry-
onic cortical neurons. As described before, stimulation with
preclustered recombinant ephrin-B3-Fc resulted in growth-
cone collapse as compared with an unstimulated condition and
a condition stimulated with Fc only (Fig. 7). As expected, KYL
peptide antagonized this effect on growth-cone collapse. Nb 53
as well as Nb 39 also inhibited the growth-cone collapse effect
mediated by ephrin-B3-Fc at the concentration of 1 M, a con-
centration at which the KYL peptide was ineffective (Fig. 7).
Nb stability in plasma
We incubatedNb 39 andNb 53 in heparinizedmouse plasma
at 37 °C for up to 168 h (7 days) to study the stability in plasma
and obtained aliquots at different time points. We determined
the stability of Nbs with Western blot using an anti-HA anti-
body. Some cleavage products could be observed from 24 h
onward for bothNb39 and 53 (Fig. 8A).Whereas full-lengthNb
39 remained stable across the time course, full-length Nb 53
levels diminished with time from 72 h onward, suggesting that
Nb 53 is more prone to degradation in plasma than Nb 39 (Fig.
Figure 3. Selectivity for EphA4 and cross-reactivitywith other Eph receptors.Using AlphaScreen technologywe determined the selectivity of the Nbs for
EphA4 receptor and the cross-reactivity with other Eph receptors. A, next to EphA4, Nb 60 also interactedwithmany other different Eph receptors. B–G, Nb 57,
22, 39, 31, and 53 presented the highest selectivity to the EphA4 receptor. F, Nb 50 had the lowest selectivity for EphA4 as it also interactedwith EphA3, EphA6,
EphA7, and EphA8. All assays were done in duplicate, and data are represented as the mean S.D.
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Figure5.Nb39andNb53donotcompletely inhibit ephrin-A5binding to
EphA7.With Alphascreen technologywe determinedwhether Nb 39 andNb
53 could inhibit ephrin-A5 binding to EphA7. These Nbs did not completely
inhibit the interaction between ephrin-A5 and EphA7 at the highest concen-
trations tested. This assay was done in triplicate, and data are represented as
the mean S.D.
Figure 6. Nbs inhibit ephrin-induced EphA4 phosphorylation. With the
PathHunter assay we could determine that Nb 39 and Nb 53 completely
inhibited EphA4 phosphorylation triggered by ephrin-A1 binding, even at a
lower concentration than the KYL peptide. All assays were performed in trip-
licate, and data are represented as the mean S.D.
Figure 4. Nbs competewith ephrin ligands in binding EphA4.WithAlphaScreen technologywedetermined the capability of theNbs to inhibit the binding
to EphA4 LBD. A,D, E, andH, Nb 22 and 31 could not completely inhibit ephrin-ligand binding to EphA4 LBD, whereas Nb 39 and Nb 53 succeeded in doing so
even at a lower concentration of the KYL peptide, which was used as a positive control. B, F, and G, Nb 22 did not show complete inhibition, and Nb 39, Nb 53,
and Nb 31 showed complete inhibition of ligand binding at a lower concentration of the KYL peptide. C, Nb 39 and 53 showed complete inhibition of ligand
binding at a lower concentrationofNb22,Nb31. and theKYLpeptide. Trend-lines are only shownwhen complete inhibitionwas reached. All assaysweredone
in duplicate, and data are represented as the mean S.D.
EphA4 inhibiting Nanobodies
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8, A and B). No degradation products were detected for any of
the Nbs after incubation in PBS at 37 °C for the same time-
course length (Fig. 8C). In addition we studied by Alphascreen
technology whether the binding capacity of Nbs to EphA4
receptor was altered after incubating the Nbs in plasma. After
72 h of incubation in plasma at 37 °C, Nbs were still capable of
binding EphA4 LBD (Fig. 8D).
Discussion
In view of EphA4’s role in normal physiology as well as in
cancer and neurodegeneration, the generation of potent and
selective antagonists against this receptor is of great interest.
The EphA4 LBDmay be a better target than its tyrosine kinase
moiety because of the difficulty to obtain selective Eph tyrosine
kinase inhibitors and because of the need for suchmolecules to
enter the cell. Here we show for the first time the generation of
single domain antibodies targeting the LBD of EphA4.
Nbs are in many ways superior to small molecules when tar-
geting the LBD of Eph receptor proteins, as high affinity bind-
ing of the LBD requires the coverage of the protein interaction
surface (900Å2 for EphA4) to block the interactionwith EphA4
ligands. Both Nb 39 and Nb 53 were able to block the interac-
tion of EphA4 with all ephrin ligands and to inhibit ephrin-
induced phosphorylation of EphA4 and growth-cone collapse
triggered by ephrin-B3 binding to endogenous EphA4.
In previous studies Nbs were used to fix receptors in one
conformation (28, 37). As a consequenceNbs are an ideal probe
to target dynamic structures such as the EphA4 LBD (2, 4, 17).
Four different conformations have been reported for the EphA4
LBD: a conformation similar to other EphA receptors bound
with ephrin-A ligands (2, 38), a conformation similar to EphB
receptors bound with ephrin-B ligands (2, 4, 15), and two
unbound conformations when free in solution (17). Fixing the
EphA4 LBD in a specific conformation might limit the accessi-
bility for all or a specific class of ephrin ligands, thereby block-
ing the interaction of those ligands with the LBD.
Nb 39 and Nb 53 were most selective for EphA4 but still
showed residual binding to EphA7, suggesting that they target a
region that is not highly conserved in all Eph receptors. How-
ever, concentrations of Nb 39 and Nb 53 that strongly inhibit
Figure 7. Nbs inhibit ephrin-B3-EphA4-mediated growth-cone collapse. Nb 53 and Nb 39 (1 M) reversed ephrin-B3-mediated growth-cone collapse. A,
E17.5 cortical neurons were first treated at 24 h after culture with 1 M or 30 M KYL peptide or 1 M Nb for 30 min and then stimulated with 1 g/ml
preclustered ephrin-B3-Fc or Fc as a control for 30min in the presence of the KYL peptide or theNb. A control conditionwithout any kind of treatmentwas also
scored (control). Cellswere stainedwithAlexa Fluor 555-conjugatedphalloidin andDAPI. Growth-cone collapsewasdetermined for every neuronby analyzing
the tipof only the longest neurite (white arrowheads). Scale bar, 10m.B, percentageof growth-cone collapsewasdetermined in every experimental condition
by assessing 40–160 neurons under a Zeiss fluorescence microscope. Percentage of collapse is expressed as the mean of collapse of six independent
experiments S.D. and was compared between different conditions by one-way ANOVA followed by Tukey’s multiple comparisons post hoc test. ***, p
0.001, as compared with control and Fc conditions. #, p 0.05; ##, p 0.01 as compared with the ephrin-B3 condition.
EphA4 inhibiting Nanobodies
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EphA4 binding to ephrin ligands only partially reduced the
interaction between EphA7 and ephrin-A5. Interestingly,
EphA7 KO mice as well as rats treated with EphA7 antisense
oligonucleotides showed enhanced recovery after spinal cord
injury compared with control mice (39), similar to the effects
described for EphA4 antagonists (24). Therefore, if some bind-
ing to EphA7 would occur in addition to EphA4, this could
potentially be of benefit rather than detrimental.
In the last years extensive work has been performed aiming
to develop EphA4 antagonists with high affinity, specificity, and
with good pharmacokinetic profiles (14). One EphA4 inhibitor,
the KYL peptide, has been studied extensively inmodels of neu-
rological disorders, such as acute injuries including spinal cord
injury and stroke and neurodegenerative disorders such as ALS
and Alzheimer’s disease (10, 11). Unfortunately, this peptide
has a KD value of 1 M as determined with isothermal titra-
tion calorimetry and a very short half-life in serum (11 min in
mouse serum) (19, 24). Interestingly, a recent study reported
the generation of highly selective EphA4 antagonists with
higher potency, the cyclic peptideAPYderivatives, APY-d3 and
APY-d4 (16, 22). APY-d3 and APY-d4 have KD values of 30 nM
and 20 nM as determined with isothermal titration calorimetry
and inhibit ephrin-A5-induced phosphorylation of EphA4
with an IC50 of 240 nM and 310 nM. Both cyclic peptides are stable
in mouse plasma for72 h and are currently the best available
EphA4 inhibitors (22). Nb 39 and 53 are more potent than the
KYL peptide but similarly potent as APY-d3 and APY-d4, with
KD values in the nanomolar range, as measured with SPR.
Moreover, bothNbs could inhibit EphA4 phosphorylationwith
an IC50 of 170 nM and 261 nM, respectively. Similar to APY-d3
and APY-d4, Nb 39 and Nb 53 were stable in mouse serum for
72 h and maintained their full capability of binding EphA4
LBD. The affinity of Nbs could still be further increased
through error-prone PCR mutagenesis and/or making bispe-
cific Nbs (40, 41). Bivalent or bispecific Nbs can be obtained by
connecting two identical or different Nbs with a linker, thereby
improving the avidity. However, this strategy requires caution
in the setting of developing EphA4 antagonists, as dimerization
of Eph receptors may induce clustering and subsequently acti-
vation, similar to what is obtained with a preclustered antibody
(42).
EphA4 has been found to play a role in cancer biology and in
the pathogenesis of several neurological disorders (5). In the
central nervous system, EphA4 is highly expressed in cell bod-
ies, dendritic spines, and axons of neurons in various brain
regions (43, 44). EphA4 expression is up-regulated in axonal
stumps after injury (45) and in sprouting neurons of aged mice
after stroke, which contributes to reduced recovery (46). Fur-
thermore, blocking EphA4 inducedmore sprouting after spinal
cord injury (8). EphA4’s negative effect on axonal regeneration
is mediated through the interaction of the receptor with ephrin
ligands on surrounding cells such as muscle cells, astrocytes,
microglia, and oligodendrocytes (47). Neuronal EphA4 may
interactwith ephrin-A5 and ephrin-B2, ofwhich the expression
is highly up-regulated in reactive astrocytes after injury (48–
50). This high astrocytic ephrin-A5 expression inhibited axonal
Figure 8. Nbs are stable in plasma for at least 72 h. Nbs were incubated in heparinized mouse plasma at 37 °C until a maximum of 168 h. A, Western
blot against HA tag was performed to detect Nb 39 and Nb 53 full-length and cleavage products. B, quantifications of full-length Nb band were
normalized to the full-length band at 0h for each Nb. The means of 3–5 independent experiments S.D. are represented. Time factor was analyzed by
two-way ANOVA followed by Sidak’s multiple comparisons post hoc test. *, p  0.05; ***, p  0.001, as compared with the 0-h time point. Differences
between the two Nbswere determined by two-way ANOVA but are not identified (n.s.). C, Nb incubation in PBS did not give rise to degradation products
as detected byWestern blot. D, incubation of Nbs in plasma at 37 °C until a maximum of 72 h did not affect the capability of those in binding EphA4 LBD.
All values represent the percentage of Nb-EphA4 LBD binding respect to the 0-h time point. This assay was done in triplicate, and data are represented
as the mean  S.D.
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sprouting andmotor recovery after stroke (49). Also, ephrin-B2
expression decreased axonal sprouting, as deleting ephrin-
B2 from reactive astrocytes reduced glial scar formation and
improved recovery after spinal cord injury, and this was corre-
lated with an increased regenerative capacity of sprouting spi-
nal cord axons (45, 48, 50). Oligodendrocytes precursor cells
are glial cells responsible for remyelination during neuronal
injury or degeneration, thereby inhibiting axonal outgrowth
(51). Neuronal EphA4may interact with ephrin-A1, ephrin-A3,
ephrin-A5, ephrin-B1, and ephrin-B2, which have been identi-
fied in oligodendrocyte precursor cells and inmature oligoden-
drocytes (52–54). In addition, enhanced functional recovery
was observed in ephrin-B3 KO mice after spinal cord injury,
and blocking ephrin-B3 promotes remyelination in vivo in a rat
model of remyelination (55, 56). The relative importance of the
different surrounding cells and different ligands is not yet
known. However, as EphA4 is a promiscuous receptor, target-
ing EphA4 by blocking the interaction with all ephrin ligands
might be the most efficient therapeutic strategy against neuro-
logical diseases.
Treating neurological disorders by targeting EphA4 implies
using substances that are able to penetrate the blood brain bar-
rier (BBB) to reach their target. In acute injuries, this barrier is
impaired. In neurodegenerative diseases such as ALS, getting
drugs across the BBB remains amajor challenge despite the fact
that the BBB is abnormal in this disease (57–59). Several strat-
egies to get biologics across the BBB have been developed, such
as transcytosis through clathrin vesicles and receptor-mediated
transcytosis by targeting the low-density lipoprotein receptor,
the transferrin receptor, or the insulin receptor (60–65). Inter-
estingly, one study showed that Nbs with a high isoelectric
point can cross the BBB spontaneously (66).
Nbs also have some drawbacks. Although Nb 39 and Nb 53
remained stable in mouse plasma for 72 h, the small size of
Nbs limits their half-life to 1.5 h after in vivo administration
(67). Due to their small size they are rapidly cleared from blood
via the kidney (27). This low half-life can be overcome by link-
ing theNb to serum albumin, which can increase the half-life to
20–30 h in mice (68). In humans, this approach extended the
half-life of Nbs to 19 days (68, 69). Another strategy to increase
the half-life of Nbs is coupling polyethylene glycol (PEG)
groups to the Nbs (70). The addition of PEG groups increases
the apparent molecular weight above the glomerular filtration
limit, avoiding renal clearance and/or evades cellular clearance
mechanisms (71).
In summary, we describe for the first time the development
of Nbs that target the EphA4 LBD. We identified two Nbs that
were specific for EphA4 with residual EphA7 binding and with
KD and IC50 values in the nanomolar range. BothNbs were able
to block the interaction of EphA4 with all ephrin ligands and
inhibit EphA4 phosphorylation and the growth-cone collapse
mediated by EphA4 activation upon ephrin-B3 interaction.
These Nbs may be useful tools to study the role of the EphA4
receptor in preclinical cancer or neurodegeneration models.
Furthermore, theymay represent a starting point for an EphA4-
based therapeutic approach using Nbs.
Experimental procedures
Expression and purification of the EphA4 ligand-binding
domain
The EphA4 LBD (amino acids 22–203; Ref. 17) was cloned
from the EphA4 Human cDNA ORF clone (Origene) and
expressed in the E. coli strain BL21 codon  pICA2 trans-
formed with the pLH36Epha plasmid. Expression was induced
by isopropyl -D-1-thiogalactopyranoside under control of a
pL-promotor developed by the Protein Service Facility of VIB.
The pLH36 plasmid was provided with a His6 tag followed by a
murine caspase-3 site. Themurine caspase-3 site can be used to
remove theHis6 tag attached at theN terminus of the protein of
interest during purification. The transformed bacteria were
grown in Luria Bertani medium supplemented with ampicillin
(100g/ml) and kanamycin (50g/ml) overnight at 28 °C inoc-
ulation (1/100) in a 20-liter fermenter provided with Luria Ber-
tanimedium supplementedwith ampicillin (100g/ml) and 1%
glycerol. The initial stirring and airflow was 200 rpm and 1.5
liters/min, respectively. Furthermore, this was automatically
adapted to keep the pO2 at 30%. The temperature was kept at
28 °C. The cells were grown to an optical density of A600 nm 
1.0 and transferred at 20 °C, and expression was induced by the
addition of 1 mM isopropyl -D-1-thiogalactopyranoside over-
night. Cells were then harvested and frozen at 	20 °C. After
thawing, the cells were resuspended at 3 ml/g in 20 mM
NaH2PO4, pH 7.5, 500 mM NaCl, 20 mM imidazole, and 1 mM
phenylmethylsulfonyl fluoride. The cytoplasmic fraction was
prepared by sonication of the cells followed by centrifugation at
18,000  g for 30 min. All steps were conducted at 4 °C. The
clear supernatant was applied to a 74-ml Ni2-Sepharose 6 FF
column (GE Healthcare), equilibrated with 20 mM NaH2PO4,
pH 7.5, 500 mMNaCl, 20 mM imidazole, and 0.1% CHAPS. The
columnwas eluted with 20mMNaH2PO4, pH 7.4, 20mMNaCl,
400 mM imidazole, and 0.1% CHAPS after an extra wash step
with 50mM imidazole. The elution fraction was diluted 1⁄20 with
20 mM Tris, pH 8.0, and 0.1% CHAPS and loaded on a 20-ml
Source 15Q column (GE Healthcare) to remove contaminants.
After equilibration, the protein of interest was eluted by a linear
gradient over 20 column volumes of NaCl from 0 to 1 M in 20
mM Tris, pH, 8.0 and 0.1% CHAPS. To the EphA4-containing
fractions, activated murine caspase-3 (1/100%murine caspase-
3/Epha4) with 10 mM DTT was added to remove the His6 tag.
After a 1-h incubation at 37 °C, the reaction solution was
injected on aHiLoad 26/60 Superdex 75 prep grade with PBS as
the running solution for formulation and removal of minor
contaminants, His6 tag and murine caspase-3. The obtained
fractions were analyzed by SDS-PAGE, and the concentration
was determined using the Micro-BCA assay (Thermo Fisher
Scientific, Ghent, Belgium).
Construction of a VHH library
Nbs targeting the EphA4LBDwere obtained in collaboration
with the VIBNanobody Service Facility. An alpaca was injected
subcutaneously on days 0, 7, 14, 21, 28, and 35, each time with
250 g of human EphA4 LBD. On day 39 anticoagulated blood
was collected for lymphocyte preparation. A VHH library was
constructed as previously described (72–74) and screened for
EphA4 inhibiting Nanobodies
11460 J. Biol. Chem. (2017) 292(27) 11452–11465
 at U
CL Library Services on July 12, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the presence of antigen-specific Nbs. In brief, total RNA from
peripheral blood lymphocytes was used as the template for
first-strand cDNA synthesis with the oligo(dT) primer. Using
this cDNA, the VHH-encoding sequences were amplified by
PCR, digested with PstI and NotI, and cloned into the PstI and
NotI sites of the phagemid vector pMECS. A VHH library of
2 108 independent transformants was obtained.
Isolation of hEphA4 LBD-specific Nbs
To screen for the presence of EphA4-specific Nbs, the library
was subjected to four consecutive rounds of panning, per-
formed on solid-phase-coated EphA4 LBD (concentration:
200 g/ml, 20 g/well). The enrichment for antigen-spe-
cific phages after each round of panning was assessed by com-
paring the number of phages eluted from antigen-coated wells
with the number of phages eluted from negative control (only-
blocked) wells. These experiments suggested that the phage
population was enriched for antigen-specific phages after the
3rd and 4th round of panning. In total, 190 individual colonies
from the 3rd and 4th round (95 from each round) were ran-
domly selected and analyzed by ELISA for the presence of anti-
gen-specific Nbs in their periplasmic extracts (ELISA using
crude periplasmic extracts including soluble Nbs). Of 190 col-
onies, 41 colonies (14 and 27 from the 3rd and 4th round,
respectively) scored positive in this assay. The VHH genes of
the selected genes were sequenced to identify the different Nbs.
Expression and purification of recombinant Nbs
pMECS vectors harboring Nb genes were transformed into
WK6E. coli cells, and the transformed cells were grown in Luria
Bertani medium supplemented with ampicillin (100 g/ml)
and 0.1% glucose at 37 °C overnight. Subsequently, the cultures
were inoculated 1/100 to have 1-liter productions in Terrific
Broth medium supplemented with ampicillin (100 g/ml) and
0.1% glucose in baffles shake flasks. The temperature was kept
at 37 °C. The cells were grown to an optical density ofA600 nm
1.0 and transferred at 28 °C, and expression was induced by the
addition of 1 mM isopropyl -D-1-thiogalactopyranoside over-
night. Cells were then harvested and frozen at 	20 °C. The
expressed Nbs were extracted from the periplasm by osmotic
shock and purified usingHisGraviTrap (GEHealthcare) in par-
allel, equilibrated with 20 mMNaH2PO4, pH 7.5, 300 mMNaCl,
20 mM imidazole, and 1 mM PMSF. After loading, the columns
were washed with 20 column volumes of the same buffer. The
Nbs were first eluted with 20 mM NaH2PO4, pH 7.5, 20 mM
NaCl, 50 mm imidazole, 1 mM PMSF and then with 400 mM
imidazole in the same buffer. Finally, the Nbs were desalted to
PBS on Sephadex G25 (GEHealthcare). The obtained fractions
were analyzed with Coomassie-stained SDS-polyacrylamide
gels. Protein concentration was measured by the Micro-BCA
assay (Thermo Fisher Scientific).
Western blot
For immunoprecipitation experiments, 1 g of EphA4 LBD,
hEphA4-Fc (R&D Systems, Abingdon, UK), and mEphA4-Fc
(R&D Systems) were boiled for 10 min in reducing sample
buffer (Thermo Fisher Scientific), and proteins were separated
in a 4–12% Bis-Tris SDS-PAGE gel (Thermo Fisher Scientific).
After SDS-PAGE, the gel was transferred to Immobilon-P
membrane (Merck Millipore, Overijse, Belgium) and subse-
quently blocked with 10% Blotting-grade blocker (Bio-Rad) for
1 h at room temperature. One g Nb and mouse anti-HA anti-
body 1/1000 (clone 16B12, MMS-101P-200, lot D13FF01646,
Covance) were used to detect EphA4. To determine Nb stabil-
ity, 10 ng of Nbs were denatured with reducing sample buffer
(Thermo Fisher Scientific) and separated in a 12% Tris-glycine
SDS-PAGE gel. The gel was transferred to Immobilon-P mem-
brane, which was afterward blocked as described above. To
detect the Nbs, 1/1000 anti-HA antibody (clone C29F4, 3724S,
lot 8, Cell Signaling) was used.
Immunoprecipitation experiments
1.5 mg of protein G magnetic Dynabeads (Thermo Fisher
Scientific) was preblocked with 1% BSA for 1 h at room tem-
perature, washed 4 times with PBS, and incubated with 2.5 g
of recombinant mouse or human EphA4 protein (R&D Sys-
tems) for 10 min at room temperature. After washing 4 times
with PBS the beadswere incubatedwith 1g ofNb overnight at
4 °C. The beads were washed 4 times with PBS and boiled for 10
min in reducing sample buffer (Thermo Fisher Scientific), and
proteins were separated in a 4–12% Bis-Tris SDS-PAGE gel
(Thermo Fisher Scientific). After SDS-PAGE, the gel was trans-
ferred to Immobilon-P membrane (Merck Millipore) and sub-
sequently blocked with 10% Blotting-grade blocker (Bio-Rad)
for 1 h at room temperature. Mouse N-terminal anti-EphA4
antibody 1/1000 (EM2801, lot 1, ECM Biosciences) and mouse
anti-HA antibody 1/1000 (clone 16B12, MMS-101P-200, lot
D13FF01646, Covance) were used to detect EphA4 and Nb,
respectively. To capture EphA4 with Nb anti-HA magnetic
Dynabeads (Thermo Fisher Scientific) were used, and all the
following steps were performed as described above.
Stability experiments
To determine theNb stability in plasma, Nbs were incubated
at 37 °C at a concentration of 10 ng/l in sodium heparin not-
filtered C57BL/6 mouse plasma (BioreclamationIVT). At every
time point an aliquot was collected and diluted 1⁄10 in PBS for
furtherWestern blot analysis. As a control, Nbs were incubated
for the same time and at the same concentration at 37 °C in PBS.
Nb stability in all samples was next determined with Western
blot as described above. Statistical analysis was performed
using the two-way ANOVA followed by Sidak’s multiple com-
parisons post hoc test as indicated in the figure legends. A 95%
confidence interval was used, and values of p 0.05 were con-
sidered as statistically significant.
To determine functional stability ofNbs, theywere first incu-
bated at 37 °C in sodium heparin not-filtered C57BL/6 mouse
plasma at 500 nM concentration. At every time point and for a
maximum of 72 h, an aliquot was collected and stored for fur-
ther analysis with Alphascreen technology.
Surface plasmon resonance
The equilibrium dissociation constant (KD) and the associa-
tion (ka1 and ka2) and dissociation rates (kd and kd2) were deter-
mined using surface plasmon resonance detection on a BIA-
Core T200 (GE Healthcare). Two approaches were used. First,
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the extracellular N-terminal domain of human EphA4 was
immobilized directly onto a CM5 S series sensor chip (GE
Healthcare) using standard amine coupling. After activation of
the carboxyl moieties on the matrix on the chip surface with a
7-min injection of a 1:1 mixture of 0.4 M EDC (l-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) and 0.1 M NHS, the N-
terminal domain of human EphA4 (50 g/ml in 10 mM ace-
tate, pH 4.5) was immobilized to a predefined level of 300
response units (RU). A flow channel activated with EDC (l-eth-
yl-3-(3-dimethylaminopropyl)carbodiimide)/NHS and imme-
diately afterward blocked by ethanolamine served as reference
channel. Throughout the analysis 10 mMHepes, 150 mMNaCl,
3mMEDTA, and 0.01mMSurfactant P-20, pH 7.35, was used as
the running buffer. 20 mM glycine, pH 2.5, was used to regen-
erate the channels (remove all bound proteins). The second
approach used the anti-human Fc capture kit as described by
the manufacturer. Briefly, 8000 RU anti-human Fc antibody
was captured on the surface of the channels using amine cou-
pling as described above. In a next step, EphA4-hFc (both
human and mouse EphA4) (R&D Systems) fusion protein (2
g/ml diluted in running buffer) was injected (10 l/min for 6
min) over the channel resulting in the capture of 500 RU of
EphA4-hFc fusion protein on the surface of the channel. In this
approach, a channel with only anti-human Fc antibody served
as the reference. 3 M MgCl2 was used as regeneration buffer.
The Nbs were diluted to the indicated concentrations in run-
ning buffer and injected (60 l/min) over the channel with
immobilized EphA4 and the reference channel. After correc-
tion of the response using the responses from the reference
channel and a blank injection of running buffer over the
Eph4A-immobilized channel (double referencing), kinetic
parameters were determined using Biacore T200 evaluation
software (GE Healthcare). Interactions of Nbs with different
EphA4 recombinant proteinswere calculatedwith a 1:1 binding
model or a two-state model. The latter model was used to cal-
culate all Nb interactions with EphA4 LBD and interactions of
Nb 34, 31, and 50 with human and mouse EphA4.
AlphaScreen
To test the specificity of the Nbs for the different Eph recep-
tors, all Nbs were biotinylated with a five times molar excess of
EZ link NHS biotin (Thermo Fisher Scientific). The Nbs were
incubated with the biotin for 2 h on ice allowing the interaction
of the biotin with the primary amines on the surface of the
protein. To remove unbound biotin, dialysis was performed
with PBS in the Slide-A-Lyzermini dialysis device (10-kDa cut-
off, Thermo Fisher Scientific). Ten microliters of biotinylated
Nbs (100 nM) were incubated with 10 l of a subhooking con-
centration of mouse recombinant Eph receptor (Fc-tagged;
R&DSystems) for 1 h in standard buffer (50mMHepes, 100mM
NaCl, 0.1% Triton, and 0.1% BSA) in white opaque 384-well
microplates (PerkinElmer Life Sciences) to avoid the hooking
effect (oversaturation of donor and acceptor beads inhibiting
their association). The determined subhooking concentrations
were 10 nM for EphA2, A3, A4, A6, B2, and B6, 30 nM for EphA7
and B3, B4, and 100 nM for EphA8. Subsequently we incubated
first 1 h with 10 l of anti-IgG AlphaLISA acceptor beads (20
g/ml, PerkinElmer Life Sciences) and then incubated an addi-
tional 30min with 10l of streptavidin donor beads (20g/ml,
PerkinElmer Life Sciences). Incubation stepswere performed at
room temperature and protected from light.
To test the inhibition of interaction between EphA4 and its
different ligands, the EphA4 LBD (2 mg/ml) was biotinylated
with a 2.5molar excess of EZ linkNHS biotin (Thermo Fisher
Scientific) for 2 h on ice, allowing the interaction of the biotin
with primary amines on the surface of the protein. To remove
unbound biotin, dialysis was performed with PBS in the Slide-
A-Lyzer mini dialysis device (10-kDa cutoff, Thermo Fisher
Scientific). Five microliters of a subhooking concentration of
biotinylated EphA4 LBD (10 nM) was incubated with 5 l of
different concentrations ofNb for 1 h in standard buffer (50mM
Hepes, 100 mM NaCl, 0.1% Triton, and 0.1% BSA). Subse-
quently, 5 l of a subhooking concentration of recombinant
ephrin ligand (Fc-tagged; R&D Systems) was added and incu-
bated for 1 h at room temperature. The determined subhooking
concentrations were 3 nM for ephrin-A1 and ephrin-A4 and 10
nM for ephrin-A2/3, ephrin-A5, and ephrin-B1–3. Next, 5 l of
anti-IgG AlphaLISA acceptor beads (20 g/ml; PerkinElmer
Life Sciences) and 5 l of streptavidin donor beads (10 g/ml;
PerkinElmer Life Sciences) were added and incubated for 1 h
and 30 min, respectively, at room temperature, protected from
light. A Nb targeting superoxide dismutase 1 (SOD1) was used
as negative control in all Eph-binding assays.
To test the inhibition of EphA7 and ephrin-A5 interaction,
His-tagged human ephrin-A5 (Sino Biological, Beijing,
China) was biotinylated with a five-times molar excess of EZ
link NHS biotin (Thermo Fisher Scientific) as is described for
theNbs. Briefly, ephrin-A5was incubatedwith the biotin for 2 h
on ice and dialyzed in PBS with the Slide-A-Lyzer mini dialysis
device (10-kDa cutoff, Thermo Fisher Scientific) to remove
unboundbiotin. Fivemicroliters of a subhooking concentration
of human EphA7 (3 nM) was incubated with 5 l of different
concentrations of Nb for 1 h in standard buffer (50 mM Hepes,
100 mM NaCl, 0.1% Triton, and 0.1% BSA). Next, 5 l of sub-
hooking concentration of biotinylated ephrin-A5 ligand (30
nM) was added and incubated for 1 h at room temperature.
Finally, 5 l of anti-IgG AlphaLISA acceptor beads (20 g/ml;
PerkinElmer Life Sciences) and 5l of streptavidin donor beads
(20 g/ml; PerkinElmer Life Sciences) were added and incu-
bated for 1 h and 30 min, respectively, at room temperature,
protected from light. A control Nb targeting chicken lysozyme
was used as negative control, and untagged ephrin-A5was used
as positive control.
To determine the capability of Nbs to bind EphA4 after
plasma incubation, 500 nM Nbs preincubated in plasma were
first diluted in PBS at the time of theAlphascreen assay to reach
a final subhooking Nb concentration of 10 nM. Five microliters
of a subhooking concentration of biotinylated EphA4 LBD (10
nM) was incubated with 5l of 10 nMNb 39 andNb 53 for 1 h in
standard buffer (50 mM Hepes, 100 mM NaCl, 0.1% Triton, and
0.1%BSA).Next, 5l of anti-HAAlphaLISA acceptor beads (20
g/ml; PerkinElmer Life Sciences) and 5 l of streptavidin
donor beads (10g/ml; PerkinElmer Life Sciences) were added
and incubated for 1 h and 30 min, respectively, at room tem-
perature, protected from light. As a control, to assess the spec-
ificity of the binding, 300 nM ephrin-B2 ligand (Fc-tagged; R&D
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Systems) was incubated with EphA4 LBD for 1 h before the
addition of the Nbs.
Plates were read on the Envision Multilabel Reader
(PerkinElmer Life Sciences).
Phosphorylation assay
The amount of phosphorylation of EphA4 was determined
using the PathHunter assay (DiscoveRx Corp., Birmingham,
UK)withU2OS cells adapted for the EphA4 receptor according
tomanufacturer’s instructions. In short, a small peptide epitope
is expressed recombinantly on the intracellular C terminus of
the EphA4 receptor-tyrosine kinase. An interaction partner
containing SH2 domains is co-expressed with a larger se-
quence, termed enzyme activator (EA). Activation with
recombinant human ephrin-A1-Fc causes EphA4 receptor
dimerization, leading to cross-phosphorylation of tyrosine res-
idues on the cytoplasmic domain of the receptor. The SH2-EA
fusion protein binds the phosphorylated receptor enabling the
complementation of EA and the peptide epitope, yielding an
active -galactosidase enzyme. This interaction can be visual-
ized with a chemiluminescent substrate. Increasing concentra-
tions of the Nbs were added to the medium before ephrin-
A1-Fc stimulation. 20l of 5000 EphA4-expressing U2OS cells
were plated in 384-well plates and incubated for 24 h at 37 °C
5% CO2. Five-l Nb dilutions or vehicle were added per well
followed by incubation for 1 h at 37 °C. Fivel of ephrin-A1-Fc
(1.2g/ml) or vehiclewere added to eachwell followed by incu-
bation for 3 h at room temperature. Twelve l of detection
reagent (Galacton Star, Emerald II solution, PathHunter cell
assay buffer in relative volumes of 1:5:19, respectively) was
added, incubated for 1 h at room temperature, and read on a
Pherastar (BMG Labtech, Ortenberg, Germany). Percentage
activity was calculated as (signal	 non-stimulated control (no
ephrin added))/(ephrin-stimulated condition 	 non-stimu-
lated control))  100. Positive and negative controls were
Dasatinib and a Nb targeting Superoxide Dismutase 1 (SOD1),
respectively.
Growth-cone collapse
The cortex of E17.5 mouse embryos was dissociated by
trypsinization and trituration. Cortical neurons were cul-
tured on 13-mm-diameter coverslips coatedwith poly-L-lysine,
at a density of 15,000 cells/coverslip in minimum Eagle’s
medium (MEM) with Earle’s salt and L-glutamine and supple-
mented with 10% heat-inactivated horse serum and penicillin
and streptomycin (Thermo Fisher Scientific). Cultures were
kept in a 5% CO2 humidified incubator at 37 °C. Medium was
replaced for Neurobasal medium supplemented with B27, 500
M L-glutamine and penicillin and streptomycin (Thermo
Fisher Scientific) 4 h after plating. 24 h after plating the cultures
were incubated for 30min with KYL peptide at a concentration
of 1 M or 30 M or Nb 53 or Nb 39 at a concentration of 1 M.
Cultures were next stimulated with 1 g/ml mouse preclus-
tered ephrin-B3-Fc, or Fc (R&DSystems) as a control and for 30
min in the presence of the KYL peptide or the Nbs. Cortical
neurons were fixed for 20 min in 4% paraformaldehyde
(ThermoFisher Scientific), permeabilized in 0.2%TritonX-100
in PBS, and stainedwith Alexa Fluor 555-conjugated phalloidin
(Thermo Fisher Scientific). Growth-cone collapse was scored
for each condition under a Zeiss Axioimager M1 epifluores-
cence and brightfield upright microscope with a Zeiss A-Plan
40/0.65∞/0.17 objective (Carl Zeiss, Oberkochen, Germany).
Growth-cone collapse was considered when no lamellipodia or
filopodia were present at the tip of the longest neurite of every
scored neuron. Growth-cone collapse was scored in a blinded
manner for 40–160 neurons in every condition and experi-
ment. Imageswere obtainedwithAxiocamMRmmonochrome
digital camera and Zeiss AxioVision V 4.8.2.0 software (Carl
Zeiss) at the same magnification. Statistical analysis was per-
formed using one-way ANOVA followed by Tukey’s post hoc
test as indicated in the figure legends. A 95% confidence inter-
val was used, and values of p 0.05 were considered as statis-
tically significant.
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